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The Editorial on the Research Topic
Dysmetabolism, Obesity and Inflammation: Three Prominent Actors in the Drama of Major
Neuropsychiatric Disorders
A large and convincing body of evidence demonstrates that medical conditions associated
with chronic inflammatory and immunological abnormalities may represent risk factors
for development of neuropsychiatric disorders. Indeed obesity, dysmetabolic conditions,
including diabetes, metabolic syndrome, and autoimmune diseases are frequently associated
to the development of neurodegenerative and psychiatric illnesses. Recent data have
demonstrated that inflammatory cytokines and adipokines can interact with multiple transmitter
pathways, neuroendocrine function, synaptic plasticity, and neurocircuits relevant to behavior
regulation. Therefore, further understanding of mechanisms linking obesity, dysmetabolism, and
(neuro)inflammation to neurological and mental alterations may be especially relevant to the
treatment and prevention for such debilitating diseases that represent a major public health
concern.
Along this line, the current Research Topic provides appreciable evidence showing that activated
inflammatory responses can undermine disease-relevant affective, emotional, social, and cognitive
functions, so that inflammatory processesmay be particularly relevant for the onset and progression
of neuropsychiatric disorders.
The present volume, at which contributed eminent scholars includes 11 review articles, 1 original
research article, and 1 commentary and was organized in the attempt to cover the whole field of the
interrelationship between inflammation, dysmetabolism, and neuropsychiatric disorders.
To this regard, a very updated and comprehensive review article by Castanon et al. provided
converging evidence showing that obesitymight be associated with exacerbated neuroinflammation
leading to dysfunction in vulnerable brain regions associated with mood regulation, learning, and
memory (Castanon et al.). Their findings shed new light on the pathophysiological mechanisms
responsible for brain disorders associated to obesity and suggest innovative strategies for the
treatment of neuropsychiatric complications occurring in obese patients.
Recent data, reviewed by Theoharides et al. demonstrated that pro-inflammatory molecules
and related signaling pathways impact on multiple neurotransmitter circuits leading to synaptic
damage, neuronal loss, and the activation of other inflammatory participants (Theoharides et al.).
In particular, the authors emphasized the role of inflammation in the onset of brain “fog,” which
represents a constellation of symptoms that include reduced mental acuity and cognition, inability
to concentrate, as well as loss of short- and long-term memory. Brain “fog” may occur in patients
suffering from many neuroimmune diseases, systemic mastocytosis, or disorders of mast cells
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activation, with increase in interleukin-6 (IL-6), tumor necrosis
factor (TNF) levels. Moreover, the authors reported that the
flavone luteolin might improve attention in children with autism
and in mastocytosis patients with brain “fog” by reducing serum
levels of TNF and IL-6. Similarly, Muller et al. provided an
update about the role of inflammation in the pathogenesis of
schizophrenia and the influence of immune activation on brain
neurotransmissions. The authors also suggested an immune-
based therapeutic approach in a subgroup of schizophrenics
in whom an immune dysbalance is associated with chronic
inflammation (Muller et al.). To this regard, Bonnot et al.
emphasized the association between hidden neurometabolic
diseases and psychiatric disorders. According to the authors,
schizophrenia-like symptoms are by far the most frequent
psychiatric warning signs of neurometabolic disorders. These
morbidities have a significant impact on the life expectancy
of patients, since subjects with chronic psychoses show a 2–
3-fold increased risk of death, mostly from cardiovascular
and metabolic diseases (Bonnot et al.). Therefore, Ventriglio
et al. suggested that clinicians should screen and monitor these
comorbidities to reduce mortality rates among patients with
psychosis (Ventriglio et al.).
Aging predisposes to diseases via several mechanisms that in
part converge on inflammatory pathways. As age advances, the
immune system undergoes a process of senescence accompanied
by the increased production of inflammatory cytokines able
to affect behavioral and cognitive performances. Deleidi et al.
discussed the link between immune aging and neurological
disorders describing how metabolic changes linked to the
aging, immunosenescence, and inflammation can enhance
the development of neurodegenerative and neuropsychiatric
diseases. The authors argued that targeting age-associated
(neuro)inflammation could delay the onset or slow disease
progression (Deleidi et al.).
In this context, glial cells have been proved to exert a crucial
role. In fact, a growing body of evidence shows the remarkable
complexity of inflammatory mechanisms in Alzheimer’s disease
(AD) and how they are often driven by alterations of glial
cells functioning. In particular, the review paper by Steardo
et al. explored the dual role of astrocytes in the onset and
progression of AD. The authors questioning the validity of
the prevalent neuron-centric vision of neuropsychiatric diseases
highlighted the role of non-neuronal cells in the pathogenesis
and progression of many diseases, also suggesting that astrocytes
could be considered as promising target for future AD therapies
(Steardo et al.).
Recent human and preclinical studies provided convincing
proof that AD is a degenerative disease associated with
dysmetabolic aspects, including impairments in brain insulin
responsiveness, glucose utilization, and energy metabolism
(Barone et al., 2016). Given this background, the review paper
by Bedse et al. focused on the role of insulin signaling in the
deposition of neuritic plaques and intracellular neurofibrillary
tangles (Bedse et al.). Moreover, the authors proposed
intranasal insulin administration as potential therapeutics, since
preliminary clinical trials have shown cognition improvement
without significant side effects (Bedse et al.). Similarly, Lutz and
Meyer discussed the potential role of the pancreatic peptide
amylin as a link between metabolic and neurodegenerative
disorders in general, and type 2 diabetes mellitus and AD in
particular, emphasizing the possible influence of amylin in the
amyloidogenetic process, and providing the rationale for an
amylin-based strategy in the treatment of AD (Lutz and Meyer).
However, although the link between dysmetabolism,
obesity, inflammation, and neuropsychiatric/neurodegenerative
disorders was extensively investigated in adulthood, there was
no convincing literature demonstrating a positive correlation
between maternal dysmetabolism and child’s mental health. In
this perspective, Rivera et al. summarized studies highlighting
maternal obesity as one of the major risk factors for the
development of mental health disorders in the offspring.
Moving also from investigations carried out with animal
models of maternal obesity, they further discussed the potential
mechanisms by which such a condition impairs the development
of neuronal circuitry, even suggesting possible strategies for
prevention and therapeutic intervention (Rivera et al.).
Besides environmental factors (e.g., diet), the epigenetic
regulation of gene expression has emerged as a potential
contributor to the susceptibility and development of obesity. To
investigate the individual sensitivity to weight gain/resistance,
the research paper by Cifani et al. studied the regulation
of gene transcription of several hypothalamic neuropeptides
involved in the control of energy balance in rats developing
obesity or not, when fed with a high fat diet (Cifani et al.).
The authors provided evidence of selective and time-dependent
transcriptional regulation of target genes in obese rats compared
to non-obese counterparts (Cifani et al.).
Among the hypothalamic neuropeptides, oxytocin seems to
play a crucial role in the regulation of feeding, metabolism, and
in several behaviors associated with neuropsychiatric disorders
(Romano et al., 2013a,b). To this regard, a very comprehensive
review article by Romano et al. examined the role of oxytocin
in a variety of physiological and behavioral processes suggesting
that future research will clarify whether oxytocin may represent
a promising target for innovative neuropsychiatric treatments
(Romano et al.).
Taken together, this special issue might provide scientists and
clinicians with new insights into this emerging area of research
and it might offer more cues for the development of promising
therapeutic strategies against such devastating illnesses.
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